Results 171 to 180 of about 1,150,837 (304)

Systems biology to unravel Western diet-associated triggers in inflammatory bowel disease. [PDF]

Front Immunol
Konjar Š, Benedik E, Šestan M, Veldhoen M, Županič A.   +4 more
europepmc   +1 more source

Evolving a lingua franca and associated software infrastructure for computational systems biology: the Systems Biology Markup Language (SBML) project [PDF]

, 2004
Michael Hucka, Andrew Finney, John C. Doyle, Hiroaki Kitano, Ben Kovitz, Bruce E. Shapiro, Akira Funahashi, J. Matthews, B. Bornstein, Sarah Keating, Maria J. Schilstra   +10 more
openalex   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Bridging academia and industry: advancing systems biology and QSP education through AstraZeneca's collaborative partnerships. [PDF]

Front Syst Biol
Pichardo-Almarza C, Kimko H.
europepmc   +1 more source

Systems Biology: an information-theoretic-based thermo-statistical approach [PDF]

, 2004
Marcus V. Mesquita, Áurea R. Vasconcellos, Roberto Luzzi, S. Mascarenhas   +3 more
openalex   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Biology of the gonadotropin-releasing hormone system in gynecological cancers

, 2002
Carsten Gründker, AR Gunthert, S Westphalen, Günter Emons   +3 more
openalex   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Cancer as a System Failure

Cancer Informatics, 2007
Igor Jurisica, Dennis Wigle
doaj  

Artificial intelligence and systems biology analysis in stem cell research and therapeutics development. [PDF]

Stem Cells Transl Med
Silva-Sousa T, Nakanishi Usuda J, Al-Arawe N, Hinterseher I, Catar R, Luecht C, Vallecillo Garcia P, Riesner K, Hackel A, Schimke LF, Dutra Dias H, Salerno Filgueiras I, Nakaya HI, Camara NOS, Fischer S, Riemekasten G, Ringdén O, Penack O, Winkler T, Duda G, Fonseca DLM, Cabral-Marques O, Moll G.   +22 more
europepmc   +1 more source